Low-molecular-weight heparins

Hematology/Oncology Clinics of North America

Volumn 12, Issue 6, 1998, Pages 1251-1281

  Huang, J N ^a   Shimamura, A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

BLEEDING; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFECT; ENDOCRINE DISEASE; HUMAN; LIVER DISEASE; LUNG EMBOLISM; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0032412178     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70052-6     Document Type: Article

References (90)

1. H.P. Adams T.G. Brott R.M. Crowell Guidelines for management of patients with acute ischemic stroke: A statement for healthcare professionals from a special working group of the Stroke Council, American Heart Association Stroke 25 1994 1901 1914
2. J. Albada H.K. Nieuwenhuis J.J. Sixma Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): Results of a double-blind randomized study Circulation 80 1989 935 940
3. D.R. Anderson B.J. O'Brien M.N. Levine Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty Ann Intern Med 119 1993 1105 1112
4. G. Bratt W. Aberg M. Johansson Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT) Thromb Haemost 64 1990 506 510
5. J.F. Cade M.R. Buchanan B. Boneu A comparison of the antithrombotic and haemorrhagic effects of low molecular heparin fractions: The influence of the method of preparation Thromb Res 35 1984 613 625
6. C. Caranobe A. Barret A.M. Gabaig Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits Thromb Res 40 1985 129 133
7. C.J. Carter J.G. Kelton J. Hirsh The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits Blood 59 1982 1239 1245
8. J.H. Chesebro Treatment of arterial thrombosis with low molecular weight heparins Semin Hematol 34 suppl 4 1997 26 34
9. M. Cohen C. Demers E.P. Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease N Engl J Med 337 1997 447 452
10. R. Collins A. Scrimgeour S. Yusuf Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: Overview of results of randomized trials in general, orthopedic and urologic surgery N Engl J Med 318 1988 1162 1173
11. R. Dahan D. Houlbert C. Caulin Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial Haemostasis 16 1986 159 164
12. M. Dechavanne D. Ville M. Berruyer Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery Haemostasis 19 1989 5 12
13. M. Drummond M. Aristides L. Davies C. Forbes Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery Br J Surg 81 1994 1742 1746
14. M. Dulitzki R. Pauzner P. Langevitz Low molecular weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies Obstet Gynecol 87 1996 380 383
15. P. Duroux A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: A collaborative European multicentre study Thromb Haemost 65 1991 251 256
16. European Fraxiparin Study (EFS) Group Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery Br J Surg 75 1988 1058 1063
17. J. Fareed W. Jeske D. Hoppensteadt Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 22 suppl 1 1996 77 91
18. Fragmin during Instability in Coronary Artery Disease (FRISC) study group Low-molecular-weight heparin during instability in coronary artery disease Lancet 347 1996 561 568
19. W.H. Geerts R.M. Jay K.I. Code A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma N Engl J Med 335 1996 701 707
20. D. Green M.Y. Lee A.C. Lim Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin Ann Intern Med 113 1990 571 574
21. E.P. Gurfinkel E.J. Manos R.I. Mejail Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia J Am Coll Cardiol 26 1995 313 318
22. K. Hamulyak A.W.A. Lensing J. van der Meer Subcutaneous low-molecular-weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Thromb Haemost 74 1995 1428 1431
23. J. Harenberg K. Huck H. Bratsch Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis Haemostasis 20 suppl 1 1990 205 219
24. J. Harenberg P. Roebruck D.L. Heene Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients Haemostasis 26 1996 127 139
25. J. Harenberg B. Wurzner R. Zimmerman Bioavailability and antagonization of the low molecular weight heparin CY216 in man Thromb Res 44 1986 549 554
26. J.A. Heit S.D. Berkowitz R. Bona Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: A double-blind, dose-ranging study Thromb Haemost 77 1997 32 38
27. J. Hirsh Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis Semin Hematol 34 suppl 4 1997 20 25
28. J. Hirsh M.N. Levine Low molecular weight heparin Blood 79 1992 1 17
29. J. Hirsh R. Raschke T.E. Warkentin Heparin: Mechanism of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety Chest 108 1995 258S 275S
30. R. Hull G. Raskob G. Pineo A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation N Engl J Med 329 1993 1370 1376
31. R.D. Hull G.E. Raskob D. Rosenbloom Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin: An economic perspective Arch Intern Medicine 157 1997 289 294
32. R.D. Hull G.E. Raskob G. Pineo Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis N Engl J Med 326 1992 975 982
33. R.D. Hull G.E. Raskob G.F. Pineo Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation: An economic perspective Arch Intern Med 157 1997 298 303
34. B.J. Hunt H.-A. Doughty G. Majumdar Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies Thromb Haemost 77 1997 39 43
35. L.N. Jorgensen P. Wille-Jørgensen O. Hauch Prophylaxis of postoperative thromboembolism with low molecular weight heparins Br J Surg 80 1993 689 704
36. V.V. Kakkar Low molecular weight heparins: Prophylaxis of venous thromboembolism in surgical patients Semin Hematol 34 suppl 4 1997 9 19
37. V.V. Kakkar O. Boeckl B. Boneu Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial World J Surg 21 1997 2 9
38. V.V. Kakkar A.T. Cohen R.A. Edmonson Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery Lancet 341 1993 259 265
39. R. Kay K.S. Wong U.L. Yu Low-molecular-weight heparin for the treatment of acute ischemic stroke N Engl J Med 333 1995 1588 1593
40. C.M. Kessler Low molecular weight heparins: Practical considerations Semin Hematol 34 suppl 4 1997 35 42
41. W. Klein A. Buchwald S.E. Hillis Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC) Circulation 96 1997 61 68
42. Knoll Pharma: Product Monograph Clivarine (reviparin sodium), 1996
43. A. Koch S. Bouges S. Ziegler Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analyses Br J Surg 84 1997 750 759
44. M.M.W. Koopman P. Prandoni F. Piovella Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home N Engl J Med 334 1996 682 687
45. J.R. Leclerc W.H. Geerts L. Desjardins Prevention of venous thromboembolism after knee arthroplasty: A randomized, double-blind trial comparing enoxaparin with warfarin Ann Intern Med 124 1996 619 626
46. A. Leizorovicz M.C. Haugh F.-R. Chapuis Low molecular weight heparin in prevention of perioperative thrombosis Br Med J 305 1992 913 920
47. A. Leizorovicz G. Simonneau H. Decousus Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis BMJ 309 1994 299 304
48. A.W.A. Lensing M.H. Prins B.L. Davidson Treatment of deep venous thrombosis with low-molecular-weight heparins Arch Intern Med 155 1995 601 607
49. Leo Laboratories Canada Ltd: Product Monograph Innohep: Tinzaparin sodium injection anticoagulant/antithrombotic agent (low molecular weight heparin), 1997
50. H. Levesque S. Verdier N. Cailleux Low molecular weight heparins and hypoaldosteronism BMJ 300 1990 1437 1438
51. M. Levine M. Gent J. Hirsh A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis N Engl J Med 334 1996 677 681
52. M.N. Levine J. Hirsh M. Gent Prevention of deep vein thrombosis after elective hip surgery: A randomized trial comparing low molecular weight heparin with standard unfractionated heparin Ann Intern Med 114 1991 545 551
53. P.F. Leyvraz F. Bachmann J. Hoek Prevention of deep vein thrombosis after hip replacement: Randomised comparison between unfractionated heparin and low molecular weight heparin BMJ 303 1991 543 548
54. M.M. Lumpkin Reports of epidural or spinal hematomas with the concurrent use of low molecular weight heparin and spinal/epidural anesthesia or spinal puncture 1997 FDA public health advisory
55. P.W. Majerus G.J.J. Broze J.P. Miletich Anticoagulant, thrombolytic, and antiplatelet drugs J.G. Hardman A.G. Gilman L.E. Limbard Goodman & Gillman's The Pharmacological Basis of Therapeutics ed 9 1996 McGraw Hill New York 1341 1359
56. D.B. Mark P.A. Cowper S.D. Berkowitz Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial Circulation 97 1998 1702 1707
57. P. Massicotte M. Adams V. Marzinotto Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study J Pediatr 128 1996 313 318
58. S.T. McCarthy J.J. Turner D. Robertson Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke Lancet 2 1977 800 801
59. G. Meyer F. Brenot G. Pacouret Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: An open randomized pilot study Thromb Haemost 74 1995 1432 1435
60. J.M. Muir J. Hirsh J.I. Weitz A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats Blood 89 1997 3236 3242
61. C. Nelson-Piercy E.A. Letsky M. de Swiet Low-molecular heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk Am J Obstet Gynecol 176 1997 1062 1068
62. M.T. Nurmohamed F.R. Rosendaal H.R. Buller Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis Lancet 340 1992 152 156
63. M.T. Nurmohamed H. ten Cate J.W. ten Cate Low molecular weight heparin(oid)s: Clinical investigations and practical recommendations Drugs 53 1997 736 751
64. A.J. Palmer K. Koppenhagen B. Kirchhof Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thromboembolism prophylaxis in orthopaedic surgery: A meta-analysis of randomised clinical trials Haemostasis 27 1997 75 84
65. A.J. Palmer W. Schramm B. Kirchhof Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: A meta-analysis of randomised clinical trials Haemostasis 27 1997 65 74
66. G.F. Pineo R.D. Hull Unfractionated and low-molecular-weight heparin: Comparisons and current recommendations Med Clin North Am 82 1998 587 599
67. G.F. Pineo R.D. Hull Low-molecular-weight heparin: Prophylaxis and treatment of venous thromboembolism Annu Rev Med 48 1997 79 91
68. P. Prandoni A.W. Lensing H.R. Buller Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis Lancet 339 1992 441 445
69. M.H. Prins R. Gelsema A.K. Sing Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients Haemostasis 19 1989 245 250
70. C. Rasmussen J. Wadt B. Jacobsen Thromboembolic prophylaxis with low molecular weight heparin during pregnancy Int J Gynecol Obstet 47 1994 121 125
71. R.D. Rosenberg Biochemistry and pharmacology of low molecular weight heparin Semin Hematol 34 suppl 4 1997 2 8
72. R.D. Rosenberg K.A. Bauer The heparin-antithrombin system: A natural anticoagulant mechanism R.W. Colman J. Hirsh V.J. Marder E.W. Salzman Hemostasis and Thrombosis: Basic Principles and Clinical Practice ed 3 1994 Lippincott Philadelphia 837 860
73. P.M. Sandset T. Dahl M. Stiris A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke Semin Thromb Hemost 16 suppl 1990 25 33
74. P. Sie M. Petitou J.-C. Lormeau Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II Biochim Biophys Acta 966 1988 188 195
75. G. Simonneau B. Charbonnier H. Decousus Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis Arch Intern Med 153 1993 1541 1546
76. G. Simonneau H. Sors B. Charbonnier A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism N Engl J Med 337 1997 663 669
77. S.A. Spinler J.J. Nawarskas Low-molecular-weight heparins for acute coronary syndromes Ann Pharmacother 32 1998 103 110
78. T.E. Spiro R.H. Fitzgerald A.A. Tronbridge Enoxaparin, a low molecular weight heparin, and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery Blood 84 1994 246A
79. The Columbus Investigators Low-molecular-weight heparin in the treatment of patients with venous thromboembolism N Engl J Med 337 1997 657 662
80. The German Hip Arthroplasty Trial (GHAT) Group Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement Archives of Orthopaedic and Trauma Surgery 111 1992 110 120
81. The Publication Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators: Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial JAMA 279 1998 1265 1272
82. The RD Heparin Arthroplasty Group Rd heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty J Bone Joint Surg 76-A 1994 1174 1185
83. D.P. Thomas Does low molecular weight heparin cause less bleeding? Thromb Haemost 78 1997 1422 1425
84. A.G.G. Turpie M. Gent R. Cote A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke Ann Intern Med 117 1992 353 357
85. A.G.G. Turpie J. Hirsh R.M. Jay Double-blind randomised trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke Lancet 1 1987 523 526
86. A. van den Belt P.M.M. Bossuy M.H. Prins Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis—an economic evaluation Thromb Haemost 79 1998 259 263
87. J. Van Ryn-McKenna L. Cai F.A. Ofosu Neutralization of enoxaparine-induced bleeding by protamine sulfate Thromb Haemost 63 1990 271 274
88. T.E. Warkentin M.N. Levine J. Hirsh Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1995 1330 1335
89. C. Warlow D. Ogston A.S. Douglas Venous thrombosis following strokes Lancet 1 1972 1305 1306
90. J.I. Weitz Low-molecular-weight heparins N Engl J Med 337 1997 688 698